Feb 17, 2024
Alnylam Pharmaceuticals Inc: Surging Revenue Fails to Yield Profitability in Q4 2023 https://csimarket.com/stocks/news.php?code=ALNY&date=2024-02-16095924&utm_source=dlvr.it&utm_medium=tumblr
Loading...
seen from United States
seen from Belgium
seen from Germany
seen from France
seen from Japan
seen from Belgium
seen from Thailand
seen from Austria
seen from United States
seen from Germany
seen from United Kingdom
seen from Japan
seen from France
seen from China
seen from France
seen from Italy
seen from France
seen from United States
seen from United States
seen from China
Alnylam Pharmaceuticals Inc: Surging Revenue Fails to Yield Profitability in Q4 2023 https://csimarket.com/stocks/news.php?code=ALNY&date=2024-02-16095924&utm_source=dlvr.it&utm_medium=tumblr
Anya is live and ready to show you everything. Watch her strip, dance, and perform exclusive shows just for you. Interact in real-time and make your fantasies come true.
Free to watch • No registration required • HD streaming
Bio-Techne (TECH:NAS) Fundamental Valuation Report
Bio-Techne (TECH:NAS) Fundamental Valuation Report
Fundamental Valuation Report
Bio-Techne(TECH:NAS) Healthcare:Biotechnology
This Report was generated using the…
View On WordPress
Motley Fool: Alnylam Adds on Sales, Looks to Pipeline for Further Growth
Motley Fool: Alnylam Adds on Sales, Looks to Pipeline for Further Growth
Alnylam Pharmaceuticals (NASDAQ:ALNY) continued its launch of Onpattro for transthyretin-mediated amyloidosis with solid quarter-over-quarter growth as the biotech looks to its pipeline to further boost its revenue.
Alnylam Pharmaceuticals results: The raw numbers
Metric
Q2 2019
Q2 2018
Change
Revenue
$44.7 million
$29.9 million
49%
Income from operations
($23…
View On WordPress
Alnylam Pharmaceuticals posts narrower-than-expected Q2 loss
Alnylam Pharmaceuticals posts narrower-than-expected Q2 loss
Alnylam Pharmaceuticals (NASDAQ: ALNY) reported a wider loss in the second quarter of 2019 due to higher costs and expenses. The bottom line was narrower than the analysts’ expectations, while the top line missed consensus estimates. Further, the company narrowed its adjusted R&D and SG&A expenses guidance for the full year 2019.
Net loss was $219.48 million or $2.02 per share, wider than a loss…
View On WordPress
Dropping The 52 Week Low, Alnylam Pharmaceuticals, Inc. (Nasdaq:ALNY) Closing At $63.30
Dropping The 52 Week Low, Alnylam Pharmaceuticals, Inc. (Nasdaq:ALNY) Closing At $63.30
Alnylam Pharmaceuticals, Inc. (Nasdaq:ALNY)
December 22nd, 2018 Amidst falling markets Alnylam Pharmaceuticals, Inc. finished Friday’s trading session down 3.81%, a $2.51 decrease to close on $63.30. As well as the drop in value, Alnylam Pharmaceuticals, Inc. hit a new 52 week low of $61.78, breaking the previous low of $63.57 from earlier this August. Alnylam Pharmaceuticals, Inc. bounced 9.36%…
View On WordPress
Anya is live and ready to show you everything. Watch her strip, dance, and perform exclusive shows just for you. Interact in real-time and make your fantasies come true.
Free to watch • No registration required • HD streaming
Analysts Estimate Higher Value for Alnylam Pharmaceuticals, Inc. (Nasdaq:ALNY), Closing The Day At $117.55
Analysts Estimate Higher Value for Alnylam Pharmaceuticals, Inc. (Nasdaq:ALNY), Closing The Day At $117.55
Alnylam Pharmaceuticals, Inc. (Nasdaq:ALNY)
August 28th, 2018
Amidst rising markets Alnylam Pharmaceuticals, Inc. closed the day up $4.96 Tuesday, up 4.41%, closing at $117.55. (more…)
View On WordPress
Alnylam Pharmaceuticals (ALNY:NAS) Fundamental Valuation Report
Alnylam Pharmaceuticals (ALNY:NAS) Fundamental Valuation Report
Print This Report was generated using the tools available on StockCalc.com. Patchell Brook Equity Analytics Inc. emphasizes that the user assumes all risks associated with the use of this report or the Stockcalc website including, but not limited to, all terms and conditions mentioned in the legal disclaimer. To access all of the tools on Stockcalc, including more detailed valuation reports and…
View On WordPress
Alexion Pharmaceuticals (ALXN:NAS) Fundamental Valuation Report
Alexion Pharmaceuticals (ALXN:NAS) Fundamental Valuation Report
Print This Report was generated using the tools available on StockCalc.com. Patchell Brook Equity Analytics Inc. emphasizes that the user assumes all risks associated with the use of this report or the Stockcalc website including, but not limited to, all terms and conditions mentioned in the legal disclaimer. To access all of the tools on Stockcalc, including more detailed valuation reports and…
View On WordPress